Conference Day 2, May 23

8:30 am Check-In & Coffee

8:55 am Chair’s Opening Remarks

  • Saso Cemerski Executive Director, Head of ImmunoOncology Discovery US, AstraZeneca

Evolution & Innovation: Navigating Recent Approvals, Charting Future Directions, & Brainstorming to Reduce Patient Burden

9:00 am Mapping the Past, Present, & Future of Cell Engager Therapies


  • Revisit the recent development landscape of cell engagers within 7 recent approvals
  • Understand which mechanisms, modalities, and formats are demonstrating promise towards developing the next approved cell engagers
  • Reimagine future directions for cell engagers for both mono and combination therapies

9:30 am Panel Discussion: Brainstorming Combinations With CART, DDR, Cytokine-Based Therapies & Other Cell Engagers


  • Discuss potential benefits and risks of combining cell engagers with alternate cancer therapies for personalized treatment strategies
  • How can cell engager combinations be developed to reduce potential relapse while reducing the patient burden of treatment?
  • Can these combinations mitigate T cell exhaustion to improve efficacy across cancer types and reduce patient burden?

10:30 am Morning Refreshments & Networking

Pursuing the Next Generation of Cell Engagers to Create Robust Immune Responses

11:00 am A First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody (PIT565) for the Treatment of B Cell Malignancies


  • PIT565 is a first-in-class, CD19xCD3xCD2, IgG-like, trispecific antibody that targets CD19+ cells and at the same time engages CD3 and CD2 (a costimulatory receptor) on T cells, which leads to redirected T-cell cytotoxicity toward CD19-positive malignant B cell
  • Preclinical data demonstrate more robust anti-tumor response and overall T cell effector functions compared with the bispecific control
  • PIT565 is currently in a Phase I, open-label study to characterize the safety and tolerability of PIT565 in patients with R/R B-NHL and R/R B-ALL to determine recommended dose(s), schedule(s), and route(s) of administration for future studies, as well as to estimate the preliminary antitumor activity of PIT565

11:30 am Developing a Highly Specific ImmTAC Against PIWIL1, a Promising Novel Colorectal Cancer Target


Exploring a program case study accelerating towards clinic

An overview of target selection processes and engineering to ensure specific and minimize off target activity

12:00 pm Accessing Intracellular Cancer Targets via Potent & Specific TCR Mimetic (TCRm)-Based T Cell Engagers

  • Benjamin Lee Senior Vice President - Translational Medicine, Crossbow Therapeutics


  • Previously unreachable target classes amenable to TCRm-based T Cell engagers
  • Differences and similarities between soluble TCR and TCRm-based T cell engager approaches
  • Unique challenges and opportunities in developing TCRm-based T Cell Engagers

12:30 pm Lunch & Networking

1:30 pm Empowering Antibodies to Target pHLA through NextCore TCR-Like Antibodies


  • Combining combinatorial and bioinformatical approaches to develop unique TCR-Like antibodies
  • Highly specific and potent T cell engagers guided by TCR-Like antibodies towards clinical valuable intracellular targets

2:00 pm Targeting Alternative T cell Effector Pathways to Enhance the Activity of CD3-Engaging Bispecific Antibodies


  • Regeneron’s approach to improving cytotoxic T cell activity by adding co-stimulatory targeted biologics
  • Examples from hematological and solid tumors
  • Exploring what are the optimal co-stimulatory agents to activate T cells in combination with CD3 bispecifics?

2:30 pm Afternoon Break

Moving Beyond T-Cells & Unlocking More Immune Cells to Take Action & Drive Tumor Killing

2:45 pm Developing Ex Vivo Precision Gene Engineered B Cell Medicines to Create Sustainable Anti-Tumor Activity & Overcome Pharmacokinetic Shortcomings of BiTEs


  • Exploring BiTE-expressing BECMs associated with reduced tumor burden in patientderived xenograft models
  • Achieving clinically meaningful serum levels of BiTE

3:15 pm Exploiting Phagocytosis With Macrophage Engagers to Enhance Tumor Killing in Solid Tumors

  • Hongtao Lu Co-Founder & Chief Scientific Officer, Elpiscience


  • Advantage of inducing cancer death and clearance by implementing macrophage phagocytosis as compared to T cell engagers
  • Explore the development challenges of macrophage engagers in comparison to alternate cell types
  • Utilize innate immune cells for improved targeting of cancers in solid tumors

3:45 pm Chair’s Closing Remarks

  • Saso Cemerski Executive Director, Head of ImmunoOncology Discovery US, AstraZeneca